Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.42 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522512 | 1.00 | KMT2A (0.44) | KMT2AMEN1TBXAS1LMNAHDAC4 | |
| SCHEMBL6520376 | 0.91 | GPR132 (0.47) | TBXAS1LMNAHDAC4HDAC3HDAC1 | |
| SCHEMBL19983238 | 0.86 | TDP1 (0.52) | KMT2AMEN1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL22460581 | 0.84 | CYP3A4 (0.49) | KMT2AMEN1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL22460574 | 0.84 | CYP3A4 (0.49) | KMT2AMEN1RAB9ACYP3A4ALDH1A1 | |
| SCHEMBL30737258 | 0.83 | MEN1 (0.50) | KMT2AMEN1LMNAHDAC1HDAC6 | |
| SCHEMBL25658960 | 0.83 | LMNA (0.53) | KMT2AMEN1LMNAHDAC3HDAC1 | |
| SCHEMBL6524155 | 0.82 | ERAP2 (0.49) | KMT2AMEN1LMNAHDAC4HDAC3 | |
| SCHEMBL6524153 | 0.82 | ERAP2 (0.49) | KMT2AMEN1LMNAHDAC4HDAC3 | |
| SCHEMBL22460628 | 0.82 | TAS1R3 (0.55) | KMT2AMEN1LMNAHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9486534-B2 | Niacin conjugated fatty acid mixtures and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2473045-B1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2016-08-17 | — | — | EP | disclosed |
| US-9238077-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | CATABASIS PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150209439-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2015-07-30 | — | — | US | disclosed |
| US-8940903-B2 | Niacin conjugated fatty acid mixtures and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-RE45275-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-RE45261-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140228413-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| US-8304551-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304552-B2 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053990-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | KMT2A 2743/4885MEN1 1887/4885TBXAS1 1291/4885 |
| US-20140228413-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | KMT2A 2743/4885MEN1 1887/4885TBXAS1 1291/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | KMT2A 2543/4885MEN1 1682/4885TBXAS1 613/4885 |
| US-20120184585-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | KMT2A 2743/4885MEN1 1887/4885TBXAS1 1291/4885 |
| US-20150209439-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | FABP1, NAMPT, ADH1B | KMT2A 3347/4885MEN1 2228/4885TBXAS1 1191/4885 |
| US-20150352094-A1 | USE OF FATTY ACID NIACIN CONJUGATES FOR TREATING DISEASES | NAMPT, NNT, FASN | KMT2A 3150/4885MEN1 1675/4885TBXAS1 1163/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | KMT2A 2543/4885MEN1 1682/4885TBXAS1 613/4885 |
| US-20120252850-A1 | NIACIN CONJUGATED FATTY ACID MIXTURES AND THEIR USES | FABP1, NAMPT, ADH1B | KMT2A 3363/4885MEN1 2237/4885TBXAS1 1193/4885 |
| US-20180028674-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | KMT2A 2743/4885MEN1 1887/4885TBXAS1 1291/4885 |
| US-20160346397-A1 | FATTY ACID NIACIN CONJUGATES AND THEIR USES | NAMPT, NAPRT, FASN | KMT2A 2743/4885MEN1 1887/4885TBXAS1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.